Actuate Therapeutics Ownership: Private Equity Firms Hold 62%, Institutions Own 20%

Actuate Therapeutics' largest shareholders are private equity firms with 62% ownership, while institutions own 20%. The top 3 shareholders own 65% of the company. Private equity firms have significant control over the company, implying that the general public has more power to influence management and governance-related decisions. Institutions own a smaller portion of the company but may have more influence due to their professional investment expertise.

Lantern Pharma (NASDAQ: LTRN) is transforming the landscape of drug discovery and development through its proprietary AI platform, RADR®. The company leverages AI insights and biomarkers to accelerate the timeline and reduce the cost of developing new drugs, particularly in oncology.

Lantern's AI platform has significantly reduced the time for new drug programs to reach Phase 1 trials, with an average of 2.5 years, compared to the industry standard of 7.5 years [1]. This acceleration is achieved by predicting and stratifying real-world patients for clinical trials with 88% accuracy, and by compressing the timeline of early-stage drug development by 70% and reducing costs by 80%.

The company's pipeline includes 12 disclosed and collaborative lead drug programs, with notable successes such as LP-300 for non-small cell lung cancer in never smokers, which is currently in a Phase 2 trial. Lantern's AI-driven model has multiple routes towards success, including drug discovery, drug repositioning, and trial acceleration with biopharma partners.

Institutional investors and private equity firms play a significant role in Lantern's shareholding structure. Private equity firms hold 62% of the company, with institutions owning 20%. The top three shareholders collectively own 65% of the company, indicating a strong influence over management and governance decisions [2].

Lantern's diverse and unique pipeline of drug programs, powered by its AI platform, positions the company as a leader in the AI-driven drug development space. The company's ability to accelerate drug development timelines and reduce costs makes it an attractive investment opportunity for both institutional and private investors.

References:
[1] Lantern Pharma Corporate Overview, August 12th 2025, NASDAQ: LTRN [https://www.marketscreener.com/news/lantern-pharma-corporate-overview-ce7c51dade8cf121](https://www.marketscreener.com/news/lantern-pharma-corporate-overview-ce7c51dade8cf121)
[2] Actuate Therapeutics Shareholder Information, July 02, 2025